Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Geriatric Oncology|September 28, 2013
Treatment of breast cancer in the elderly: a prospective, population-based Swiss studyM Joerger, B Thürlimann, A Savidan, et al.
British Journal of Clinical Pharmacology|October 16, 2007
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic studyM Joerger, A D R Huitema, M T Huizing, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2021
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinomaM Gachechiladze, I Uberall, D Skanderova, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2011
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabineM Joerger, J A Burgers, P Baas, et al.
ESMO Open|October 30, 2025
A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK)K-L Koster, I Colombo, S Hayoz, et al.
Investigational New Drugs|March 21, 2017
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumorsA Stathis, D Hess, R von Moos, et al.
Lung Cancer (Amsterdam, Netherlands)|June 15, 2014
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)M Joerger, F Baty, M Früh, et al.
Cancer Chemotherapy and Pharmacology|February 14, 2015
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapyM Joerger, A D R Huitema, H Boot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)M Joerger, J von Pawel, S Kraff, et al.
Pageof 5